A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults
Clinical trial NCT06371534 · UNKNOWN
Trial details
- NCT number
- NCT06371534
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-12
- Primary completion
- 2025-04-01
- Enrollment
- 228
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.